Impact of tozinameran (BNT162b2) mRNA vaccine on kidney transplant and chronic dialysis patients: 3-5 months follow-up.
COVID-19
End-stage renal disease
Hemodialysis
Kidney transplantation
Peritoneal dialysis
Vaccines
Viral infections
Journal
Journal of nephrology
ISSN: 1724-6059
Titre abrégé: J Nephrol
Pays: Italy
ID NLM: 9012268
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
01
08
2021
accepted:
11
11
2021
pubmed:
7
1
2022
medline:
4
2
2022
entrez:
6
1
2022
Statut:
ppublish
Résumé
Determining the humoral immunogenicity of tozinameran (BNT162b2) in patients requiring chronic renal replacement therapy, and its impact on COVID-19 morbidity several months after vaccination, may guide risk assessment and changes in vaccination policy. In a prospective post-vaccination cohort study with up to 5 months follow-up we studied outpatient dialysis and kidney transplant patients and respective healthcare teams. Outcomes were anti S1/S2 antibody responses to vaccine or infection, and infection rate during follow-up. One hundred seventy-five dialysis patients (40% women, 65 ± 15 years), 252 kidney transplant patients (33% women, 54 ± 14 years) and 71 controls (65% women, 44 ± 14 years) were followed. Three months or longer after vaccination we detected anti S1/S2 IgG antibodies in 79% of dialysis patients, 42% of transplant recipients and 100% of controls, whereas respective rates after infection were 94%, 69% and 100%. Predictors of non-response were older age, diabetes, history of cancer, lower lymphocyte count and lower vitamin-D levels. Factors associated with lower antibody levels in dialysis patients were modality (hemodialysis vs peritoneal) and high serum ferritin levels. In transplant patients, hypertension and higher calcineurin or mTOR inhibitor drug levels were linked with lower antibody response. Vaccination was associated with fewer subsequent infections (HR 0.23, p < 0.05). Moreover, higher antibody levels (particularly above 59 AU/ml) were associated with fewer events, with a HR 0.41 for each unit increased in log Dialysis patients, and more strikingly kidney transplant recipients, mounted reduced antibody response to COVID-19 mRNA vaccination. Lesser humoral response was associated with more infections. Measures to identify and protect non-responsive patients are required.
Sections du résumé
BACKGROUND
BACKGROUND
Determining the humoral immunogenicity of tozinameran (BNT162b2) in patients requiring chronic renal replacement therapy, and its impact on COVID-19 morbidity several months after vaccination, may guide risk assessment and changes in vaccination policy.
METHODS
METHODS
In a prospective post-vaccination cohort study with up to 5 months follow-up we studied outpatient dialysis and kidney transplant patients and respective healthcare teams. Outcomes were anti S1/S2 antibody responses to vaccine or infection, and infection rate during follow-up.
RESULTS
RESULTS
One hundred seventy-five dialysis patients (40% women, 65 ± 15 years), 252 kidney transplant patients (33% women, 54 ± 14 years) and 71 controls (65% women, 44 ± 14 years) were followed. Three months or longer after vaccination we detected anti S1/S2 IgG antibodies in 79% of dialysis patients, 42% of transplant recipients and 100% of controls, whereas respective rates after infection were 94%, 69% and 100%. Predictors of non-response were older age, diabetes, history of cancer, lower lymphocyte count and lower vitamin-D levels. Factors associated with lower antibody levels in dialysis patients were modality (hemodialysis vs peritoneal) and high serum ferritin levels. In transplant patients, hypertension and higher calcineurin or mTOR inhibitor drug levels were linked with lower antibody response. Vaccination was associated with fewer subsequent infections (HR 0.23, p < 0.05). Moreover, higher antibody levels (particularly above 59 AU/ml) were associated with fewer events, with a HR 0.41 for each unit increased in log
CONCLUSIONS
CONCLUSIONS
Dialysis patients, and more strikingly kidney transplant recipients, mounted reduced antibody response to COVID-19 mRNA vaccination. Lesser humoral response was associated with more infections. Measures to identify and protect non-responsive patients are required.
Identifiants
pubmed: 34988942
doi: 10.1007/s40620-021-01210-y
pii: 10.1007/s40620-021-01210-y
pmc: PMC8731189
doi:
Substances chimiques
RNA, Messenger
0
Vaccines, Synthetic
0
mRNA Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
153-164Subventions
Organisme : ministry of health, state of israel
ID : Serology kits
Informations de copyright
© 2021. The Author(s) under exclusive licence to Italian Society of Nephrology.
Références
Infection. 1988;16(6):323-8
pubmed: 3065242
Am J Kidney Dis. 2020 Mar;75(3):456
pubmed: 31980253
Nat Rev Microbiol. 2011 Oct 03;9(12):889-93
pubmed: 21963800
Immune Netw. 2017 Jun;17(3):152-162
pubmed: 28680376
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669
pubmed: 33629336
J Am Soc Nephrol. 2021 May 3;32(5):1018-1020
pubmed: 33637517
Vaccine. 1987 Mar;5(1):43-8
pubmed: 3577356
Clin Infect Dis. 2021 May 20;:
pubmed: 34015106
Kidney Int Rep. 2021 Jun;6(6):1699-1700
pubmed: 33907723
Clin J Am Soc Nephrol. 2021 Jul;16(7):1037-1042
pubmed: 33824157
N Engl J Med. 2021 Oct 7;385(15):1393-1400
pubmed: 34525275
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
Med Sci Monit. 2013 Nov 18;19:1013-8
pubmed: 24241247
JAMA. 2021 Jun 1;325(21):2204-2206
pubmed: 33950155
Clin Kidney J. 2020 Oct 21;13(5):878-888
pubmed: 33354330
J Heart Lung Transplant. 2021 Aug;40(8):759-762
pubmed: 34034958
Clin Microbiol Infect. 2021 Aug;27(8):1173.e1-1173.e4
pubmed: 33957273
Vaccine. 2021 Apr 28;39(18):2537-2544
pubmed: 33814231
Ann Intern Med. 2021 Aug;174(8):1073-1080
pubmed: 34000201
J Am Soc Nephrol. 2021 May 3;32(5):1021-1024
pubmed: 33762353
Nephrol Dial Transplant. 2021 Apr 11;:
pubmed: 33839785
BMC Bioinformatics. 2010 Jul 02;11:367
pubmed: 20598126
Clin Pharmacokinet. 1992 Jun;22(6):434-46
pubmed: 1587056
Am J Transplant. 2021 Oct;21(10):3496-3499
pubmed: 33890410
Nephrol Dial Transplant. 2021 Aug 27;36(9):1709-1716
pubmed: 33999200
Nephrol Dial Transplant. 2020 Nov 1;35(11):1973-1983
pubmed: 33151337
NPJ Vaccines. 2021 May 13;6(1):74
pubmed: 33986272
N Engl J Med. 2021 May 6;384(18):1775-1777
pubmed: 33755373
Pathogens. 2021 Jan 30;10(2):
pubmed: 33573221
Am J Transplant. 2021 Aug;21(8):2719-2726
pubmed: 33866672
Viruses. 2021 Apr 25;13(5):
pubmed: 33923063
Infect Dis Ther. 2021 Jun 16;:1-14
pubmed: 34155471